Cargando…

Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter study

BACKGROUND: The relative lack of specifically targeted agents for HER2-negative metastatic breast cancer (MBC) makes the need for new agents or combination therapies to maximize clinical benefit while reducing toxicity critical. OBJECTIVES: To retrospectively analyze the efficacy and safety of eribu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Mingxia, Shao, Bin, Wan, Donggui, Liu, Jiaxuan, He, Maiyue, Chai, Yue, Sang, Die, Wang, Jiayu, Ma, Fei, Fan, Ying, Yuan, Peng, Xu, Binghe, Li, Qiao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571693/ https://www.ncbi.nlm.nih.gov/pubmed/37841751 http://dx.doi.org/10.1177/17588359231204856

Ejemplares similares

A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Improved survival in patients with isolated liver metastasis at initial diagnosis with surgery at primary and metastatic sites: A population‐based study in patients with breast cancer
por: Chai, Yue, et al.
Publicado: (2023)

Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial
por: He, Maiyue, et al.
Publicado: (2023)

Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer
por: Shingaki, Sumito, et al.
Publicado: (2020)

Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
por: Liu, Jiaxuan, et al.
Publicado: (2022)

A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
por: Takashima, Tsutomu, et al.
Publicado: (2016)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial—a multicenter retrospective study of eribulin in real life
por: Garrone, Ornella, et al.
Publicado: (2016)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

Efficacy of Oral Etoposide in Pretreated Metastatic Breast Cancer: A Multicenter Phase 2 Study
por: Yuan, Peng, et al.
Publicado: (2015)

Effect of eribulin on patients with metastatic breast cancer: multicenter retrospective observational study in Taiwan
por: Rau, Kun-Ming, et al.
Publicado: (2018)

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
por: Nakamoto, Shogo, et al.
Publicado: (2022)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer
por: Hu, Nanlin, et al.
Publicado: (2021)

Eribulin Treatment for Patients with Metastatic Breast Cancer: The UK Experience − A Multicenter Retrospective Study
por: Jafri, Mariam, et al.
Publicado: (2022)

Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review
por: Watanabe, Junichiro
Publicado: (2015)

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study
por: Hardy-Bessard, Anne-Claire, et al.
Publicado: (2020)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

A Novel Prognostic Nomogram for Predicting Survival of Hormone Receptor-Positive and HER2 Negative Advanced Breast Cancer Among the Han-Population
por: Zhu, Yimin, et al.
Publicado: (2022)

The efficacies and biomarker investigations of antiangiogenic agents and PD-1 inhibitors for metastatic soft tissue sarcoma: A multicenter retrospective study
por: Liu, Zhiyong, et al.
Publicado: (2023)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2023)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Safety of endoscopy in cancer patients on antiangiogenic agents: A retrospective multicenter outcomes study
por: Kachaamy, Toufic, et al.
Publicado: (2017)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators
por: Inoue, Kenichi, et al.
Publicado: (2018)

Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)
por: De Angelis, C., et al.
Publicado: (2021)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Predictive biomarkers of response and survival following immunotherapy with a PD-L1 inhibitor benmelstobart (TQB2450) and antiangiogenic therapy with a VEGFR inhibitor anlotinib for pretreated advanced triple negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2023)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)
por: Ohtani, Shoichiro, et al.
Publicado: (2018)

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: a multicenter retrospective study
por: Zhao, Yannan, et al.
Publicado: (2021)

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial
por: Inoue, Kenichi, et al.
Publicado: (2019)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center
por: Sirvén, Milana Bergamino, et al.
Publicado: (2019)

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer
por: Rao, Shreyas S., et al.
Publicado: (2017)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy
por: Doherty, Mark K, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1cl86rd87jnd537pkhmkq9jhe2